Medicamen Biotech Limited (MEDICAMEQ.NS)
INR 432.5
(1.32%)
INR 432.5
(1.32%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 335.16 Million INR | -32.9% |
| 2022 | 512.68 Million INR | 76.86% |
| 2021 | 289.88 Million INR | 80.71% |
| 2020 | 160.41 Million INR | -9.68% |
| 2019 | 177.59 Million INR | 11.22% |
| 2018 | 159.68 Million INR | -11.22% |
| 2017 | 179.86 Million INR | 10.4% |
| 2016 | 162.92 Million INR | 10.22% |
| 2015 | 147.81 Million INR | -10.85% |
| 2014 | 165.8 Million INR | 11.45% |
| 2013 | 148.77 Million INR | -6.33% |
| 2012 | 158.81 Million INR | -19.23% |
| 2011 | 196.63 Million INR | 2.7% |
| 2010 | 191.46 Million INR | 4.33% |
| 2009 | 183.51 Million INR | -3.1% |
| 2008 | 189.38 Million INR | 36.48% |
| 2007 | 138.75 Million INR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 76.75 Million INR | -18.21% |
| 2023 Q4 | 95.8 Million INR | -48.02% |
| 2023 FY | 344.02 Million INR | -32.9% |
| 2023 Q1 | 158.15 Million INR | 30.17% |
| 2023 Q2 | 175.67 Million INR | 11.08% |
| 2023 Q3 | 184.31 Million INR | 4.92% |
| 2022 Q1 | 120.63 Million INR | 260.18% |
| 2022 Q2 | 127.28 Million INR | 5.51% |
| 2022 Q4 | 121.49 Million INR | -15.2% |
| 2022 FY | 512.68 Million INR | 76.86% |
| 2022 Q3 | 143.27 Million INR | 12.57% |
| 2021 Q4 | -75.31 Million INR | -161.77% |
| 2021 FY | 289.88 Million INR | 80.71% |
| 2021 Q2 | 137.87 Million INR | 30.81% |
| 2021 Q1 | 105.4 Million INR | 461.82% |
| 2021 Q3 | 121.92 Million INR | -11.57% |
| 2020 Q4 | -29.13 Million INR | -147.15% |
| 2020 Q1 | 60.27 Million INR | 248.82% |
| 2020 Q3 | 61.78 Million INR | -8.44% |
| 2020 Q2 | 67.48 Million INR | 11.97% |
| 2020 FY | 160.41 Million INR | -9.68% |
| 2019 Q3 | 81.78 Million INR | 5.0% |
| 2019 Q4 | -40.49 Million INR | -149.52% |
| 2019 FY | 177.59 Million INR | 11.22% |
| 2019 Q1 | 58.42 Million INR | 238.72% |
| 2019 Q2 | 77.88 Million INR | 33.31% |
| 2018 Q4 | -42.11 Million INR | -172.1% |
| 2018 FY | 159.68 Million INR | -11.22% |
| 2018 Q3 | 58.42 Million INR | -19.69% |
| 2018 Q2 | 72.74 Million INR | 3.01% |
| 2018 Q1 | 70.62 Million INR | 254.21% |
| 2017 Q2 | 80.31 Million INR | 20.62% |
| 2017 Q1 | 66.58 Million INR | 563.83% |
| 2017 Q3 | 78.75 Million INR | -1.94% |
| 2017 Q4 | -45.79 Million INR | -158.15% |
| 2017 FY | 179.86 Million INR | 10.4% |
| 2016 Q2 | 63.77 Million INR | 19.06% |
| 2016 FY | 162.92 Million INR | 10.22% |
| 2016 Q4 | -14.35 Million INR | -123.95% |
| 2016 Q3 | 59.94 Million INR | -6.01% |
| 2016 Q1 | 53.56 Million INR | 404.79% |
| 2015 Q3 | 57.43 Million INR | 4.94% |
| 2015 FY | 147.81 Million INR | -10.85% |
| 2015 Q1 | 53.22 Million INR | 369.84% |
| 2015 Q2 | 54.72 Million INR | 2.82% |
| 2015 Q4 | -17.57 Million INR | -130.6% |
| 2014 Q4 | -19.72 Million INR | -129.91% |
| 2014 Q1 | 58.01 Million INR | 11173.93% |
| 2014 Q2 | 61.58 Million INR | 6.15% |
| 2014 Q3 | 65.93 Million INR | 7.07% |
| 2014 FY | 165.8 Million INR | 11.45% |
| 2013 Q4 | -523.86 Thousand INR | -101.21% |
| 2013 Q3 | 43.37 Million INR | -19.43% |
| 2013 Q1 | 53.04 Million INR | 1559.54% |
| 2013 Q2 | 53.83 Million INR | 1.49% |
| 2013 FY | 148.77 Million INR | -6.33% |
| 2012 Q3 | 48.32 Million INR | -23.11% |
| 2012 Q2 | 62.84 Million INR | 29.97% |
| 2012 Q1 | 48.35 Million INR | 646.26% |
| 2012 FY | 158.81 Million INR | -19.23% |
| 2012 Q4 | 3.19 Million INR | -93.39% |
| 2011 Q2 | 140.93 Million INR | 0.0% |
| 2011 Q4 | -8.85 Million INR | -112.76% |
| 2011 FY | 196.63 Million INR | 2.7% |
| 2011 Q3 | 69.35 Million INR | -50.79% |
| 2010 FY | 191.46 Million INR | 4.33% |
| 2009 FY | 183.51 Million INR | -3.1% |
| 2008 Q4 | 56.2 Million INR | 0.0% |
| 2008 FY | 189.38 Million INR | 36.48% |
| 2007 Q4 | 45.36 Million INR | 0.0% |
| 2007 FY | 138.75 Million INR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Amrutanjan Health Care Limited | 2.09 Billion INR | 83.994% |
| Biofil Chemicals and Pharmaceuticals Limited | 6.82 Million INR | -4814.472% |
| Caplin Point Laboratories Limited | 2.17 Billion INR | 84.586% |
| FDC Limited | 3.49 Billion INR | 90.423% |
| Gufic Biosciences Limited | 1.18 Billion INR | 71.754% |
| Hikal Limited | 4.46 Billion INR | 92.491% |
| Ind-Swift Laboratories Limited | 2.12 Billion INR | 84.221% |
| IOL Chemicals and Pharmaceuticals Limited | 2.2 Billion INR | 84.772% |
| Kilitch Drugs (India) Limited | 412.42 Million INR | 18.733% |
| Medico Remedies Limited | 59.67 Million INR | -461.654% |
| Nectar Lifesciences Limited | 932.7 Million INR | 64.065% |
| Par Drugs and Chemicals Limited | 58.28 Million INR | -475.019% |
| RPG Life Sciences Limited | 1.63 Billion INR | 79.507% |
| Sequent Scientific Limited | 2.9 Billion INR | 88.45% |
| Shilpa Medicare Limited | 3.33 Billion INR | 89.948% |
| Sigachi Industries Limited | 579.88 Million INR | 42.201% |
| Themis Medicare Limited | 1.12 Billion INR | 70.228% |
| Unichem Laboratories Limited | 6.72 Billion INR | 95.017% |
| Venus Remedies Limited | 1.91 Billion INR | 82.51% |
| Wanbury Limited | 978.96 Million INR | 65.763% |
| ZIM Laboratories Limited | 1.01 Billion INR | 66.915% |
| Lupin Limited | 125.09 Billion INR | 99.732% |
| Innova Captab Limited | 931.03 Million INR | 64.0% |
| Ind-Swift Limited | 946.56 Million INR | 64.591% |
| Bajaj HealthCare Limited | 985.34 Million INR | 65.985% |
| Aurobindo Pharma Limited | 55.65 Billion INR | 99.398% |
| Solara Active Pharma Sciences Limited | 2.55 Billion INR | 86.877% |
| AstraZeneca Pharma India Limited | 2.47 Billion INR | 86.45% |
| Mangalam Drugs & Organics Limited | 162.22 Million INR | -106.602% |
| Morepen Laboratories Limited | 1.98 Billion INR | 83.136% |
| Laurus Labs Limited | 11.9 Billion INR | 97.186% |
| Aarti Drugs Limited | 1.16 Billion INR | 71.291% |
| Glenmark Life Sciences Limited | 11.64 Billion INR | 97.121% |
| Alembic Limited | 872.45 Million INR | 61.584% |
| Alembic Pharmaceuticals Limited | 15.86 Billion INR | 97.888% |
| Glenmark Pharmaceuticals Limited | 46.95 Billion INR | 99.286% |
| Vaishali Pharma Limited | 84.02 Million INR | -298.871% |
| Aarti Pharmalabs Limited | 3.07 Billion INR | 89.098% |
| Jagsonpal Pharmaceuticals Limited | 438.55 Million INR | 23.574% |
| Jubilant Pharmova Limited | 14.45 Billion INR | 97.681% |
| Eris Lifesciences Limited | 4.94 Billion INR | 93.219% |
| Windlas Biotech Limited | 1 Billion INR | 66.7% |
| Sun Pharmaceutical Industries Limited | 154.18 Billion INR | 99.783% |
| Lincoln Pharmaceuticals Limited | 1.07 Billion INR | 68.798% |
| Orchid Pharma Limited | 800.77 Million INR | 58.144% |
| Albert David Limited | 1.02 Billion INR | 67.337% |
| Hester Biosciences Limited | 908.84 Million INR | 63.121% |
| Sakar Healthcare Limited | 204.07 Million INR | -64.234% |
| Suven Pharmaceuticals Limited | 1.4 Billion INR | 76.107% |
| Procter & Gamble Health Limited | 2.99 Billion INR | 88.811% |
| Divi's Laboratories Limited | 14.17 Billion INR | 97.635% |
| Mankind Pharma Limited | 29.27 Billion INR | 98.855% |
| Neuland Laboratories Limited | 2.92 Billion INR | 88.56% |
| J. B. Chemicals & Pharmaceuticals Limited | 14.79 Billion INR | 97.734% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 99.732% |
| Wockhardt Limited | 8.48 Billion INR | 96.048% |
| Bal Pharma Limited | 555.62 Million INR | 39.678% |
| Dr. Reddy's Laboratories Limited | 95.87 Billion INR | 99.65% |
| Bliss GVS Pharma Limited | 1.41 Billion INR | 76.384% |
| Alkem Laboratories Limited | 32.83 Billion INR | 98.979% |
| Valiant Laboratories Limited | 138.02 Million INR | -142.824% |
| Ajanta Pharma Limited | 30.46 Billion INR | 98.9% |
| Bafna Pharmaceuticals Limited | 455.58 Million INR | 26.432% |
| Aarey Drugs & Pharmaceuticals Limited | 14.21 Million INR | -2258.172% |
| Granules India Limited | 10.31 Billion INR | 96.75% |
| Ipca Laboratories Limited | 18.98 Billion INR | 98.235% |
| Brooks Laboratories Limited | 51.18 Million INR | -554.879% |
| Syncom Formulations (India) Limited | 345.63 Million INR | 3.028% |
| Piramal Enterprises Limited | 63.65 Billion INR | 99.473% |
| Torrent Pharmaceuticals Limited | 21.42 Billion INR | 98.435% |
| NATCO Pharma Limited | 10.05 Billion INR | 96.668% |
| Suven Life Sciences Limited | 109.75 Million INR | -205.391% |
| Krebs Biochemicals & Industries Limited | 46.15 Million INR | -626.161% |
| Strides Pharma Science Limited | 9.16 Billion INR | 96.342% |
| Indoco Remedies Limited | 12.06 Billion INR | 97.221% |
| Alpa Laboratories Limited | 127.38 Million INR | -163.124% |
| Lasa Supergenerics Limited | 291.17 Million INR | -15.109% |
| Sun Pharma Advanced Research Company Limited | 3.07 Billion INR | 89.107% |